Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

To describe the results of the first four rounds (T0‐T3) of prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial (designed to determine the value of screening in the four cancers), that for prostate cancer is evaluating whether annual screening with prostate‐specific antigen (PSA) and a digital rectal examination (DRE) reduces prostate cancer‐specific mortality.

[1]  T. Tammela,et al.  Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial , 2004, Clinical Cancer Research.

[2]  F. Schröder,et al.  The European Randomized Study of Screening for Prostate Cancer (ERSPC): An Update , 1999, European Urology.

[3]  R. Renzetti.  The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update , 1999 .

[4]  P C Prorok,et al.  Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. , 1994, The Journal of urology.

[5]  Shandra S. Wilson.  Prostate cancer screening. , 2005, Comprehensive therapy.

[6]  Patrick C. Walsh,et al.  American Cancer Society guidelines for the early detection of cancer. , 2002, CA: a cancer journal for clinicians.

[7]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  W. Catalona,et al.  Longitudinal screening for prostate cancer with prostate-specific antigen. , 1996, JAMA.

[9]  Hans Lilja,et al.  Results of a randomized, population‐based study of biennial screening using serum prostate‐specific antigen measurement to detect prostate carcinoma , 2004, Cancer.

[10]  T. H. van der Kwast,et al.  Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening. , 2007, European urology.

[11]  F. Labrie,et al.  Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial , 1999, The Prostate.

[12]  A. D'Amico,et al.  Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. , 2006, Urology.

[13]  P C Prorok,et al.  Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. , 2000, Controlled clinical trials.

[14]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[15]  J. Gohagan,et al.  Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. , 2005, Journal of the National Cancer Institute.

[16]  G Bartsch,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001, Urology.

[17]  P. Prorok,et al.  Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening , 1996, Journal of medical screening.

[18]  T. Wilt,et al.  Screening for prostate cancer. , 2013, The Cochrane database of systematic reviews.

[19]  Robert A Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2004 , 2004, CA: a cancer journal for clinicians.